Reuters logo
4 个月前
BRIEF-Amgen Inc reports four-year follow-up results from Repatha Osler-1 study
2017年3月14日 / 晚上8点39分 / 4 个月前

BRIEF-Amgen Inc reports four-year follow-up results from Repatha Osler-1 study

1 分钟阅读

March 14 (Reuters) - Amgen Inc

* Amgen Inc - four-year follow-up results from Repatha (evolocumab) Osler-1 study

* Amgen Inc - Repatha, when added to standard of care (SOC), achieved median low-density lipoprotein cholesterol (LDL-C) reductions of 57 percent at four years

* Amgen - Repatha, when added to SOC achieved median LDL-C reductions with no new safety concerns identified Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below